Kyle Shanks, President
17045 El Camino Real
Houston, TX 77058
Office (281) 480-8899
Cell (832) 414-9520
Fax (281) 480-4998
All Rights Reserved
has evolved into a highly diverse biotechnology opportunity.
Our short-term plan is to launch an innovative cosmetic line of
products by March 31, 2011. These
products will contain valuable bio-molecules produced in Simulate
Microgravity (using exclusive NASA technology). We have achieved
outstanding testing results in these products, with further breakthroughs
sure to come.
shareholders will be rewarded by this revenue in two ways:
1) A nice return on investment through dividend payment
based on net profits of cosmetics; and
2) A portion of these net profits will be devoted to the actual
therapies involving cardio-vascular treatments, diabetes, orthopedics
and other therapies. Our shareholders will have the satisfaction
of being on the cutting edge of cosmetics development and Adult
Stem Cell therapies. We will lead breakthroughs in both areas.
Regenetech, Inc. has authorized the sale of
2 million shares of common stock. This offering is available to
Accredited Individuals and to Institutional and Corporate investors.
(Interested parties should contact us for details of the offering)
of Use The information contained on this Investor Relations web
site is provided for informational purposes only and does not constitute
an offer to sell or the solicitation of an offer to buy any securities.
The financial and other information that may be accessed on this
investor Relations page speaks only as of the particular dates referenced
in the information or the dates the information was originally issued.
This information may have since become superseded as a result of
later circumstances or events. Regenetech� does not undertake any
obligation, and disclaims any duty, to update this information.
In addition, this information may contain forward-looking statements
that are subject to various risks and uncertainties that could cause
actual outcomes or results to differ materially from those expressed
in or implied by any forward-looking statement.
Please contact us for more information using the following phone
numbers or email addresses.
Note: For security reasons, please do not send confidential or personal
information through email.
(24 hours a day / 7 days a week)